Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22966Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tsouli, S. G. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Kiortsis, D. N. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:29:21Z | - |
| dc.date.available | 2015-11-24T19:29:21Z | - |
| dc.identifier.issn | 1074-2484 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22966 | - |
| dc.rights | Default Licence | - |
| dc.subject | Angiotensin II Type 1 Receptor Blockers/administration & dosage/*therapeutic use | en |
| dc.subject | Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use | en |
| dc.subject | Cardiovascular Diseases/*drug therapy | en |
| dc.subject | Clinical Trials as Topic | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Humans | en |
| dc.subject | Hypertension/drug therapy | en |
| dc.subject | Renal Insufficiency/prevention & control | en |
| dc.subject | Renin-Angiotensin System/drug effects | en |
| dc.subject | Stroke/prevention & control | en |
| dc.title | Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16703216 | - |
| heal.identifier.secondary | http://cpt.sagepub.com/content/11/1/1.full.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | Several studies have shown that angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are useful in the treatment of hypertension, cardiovascular disease, chronic heart failure, and some types of nephropathy. In this context, dual renin-angiotensin system blockade with both angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may be more effective than treatment with each agent alone. Many clinical trials have demonstrated the beneficial effect of this combined treatment on proteinuria, hypertension, heart failure, and cardiovascular events. Moreover, these studies demonstrated that dual renin-angiotensin system blockade is generally safe and well tolerated. Long-term studies are under way to confirm these effects and also investigate the effectiveness of dual renin-angiotensin system blockade on cerebrovascular disease and prevention of type 2 diabetes mellitus. These studies are expected to define the optimal use of combination treatment in everyday clinical practice. This review considers the most important clinical trials that evaluated the effect of dual renin-angiotensin system blockade on blood pressure, heart failure, and renal function. | en |
| heal.journalName | J Cardiovasc Pharmacol Ther | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Tsouli-2006-Combined treatment w.pdf | 124.03 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
